| General Information of Drug Metabolite (DM) (ID: DM005222) |
| DM Name |
Tepotinib M506 metabolite
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2C8 (CYP2C8)
|
DME0018
|
| Oxidation - Oxidationn |
Tepotinib
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Oxidationn |
Tepotinib
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Tepotinib |
DR5499
|
Approved |
Lung cancer |
|
|
| References |
| 1 |
Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
